Diagnostic Accuracy of the Second Edition of the Paris System for Reporting High-Grade Urothelial Carcinoma in Urinary Cytology.

IF 1.6 4区医学 Q3 PATHOLOGY

Acta Cytologica Pub Date : 2024-09-18 DOI:10.1159/000541504

Anu Singh,Adil Aziz Khan,Charanjeet Ahluwalia,Sana Ahuja,Sunil Ranga

{"title":"Diagnostic Accuracy of the Second Edition of the Paris System for Reporting High-Grade Urothelial Carcinoma in Urinary Cytology.","authors":"Anu Singh,Adil Aziz Khan,Charanjeet Ahluwalia,Sana Ahuja,Sunil Ranga","doi":"10.1159/000541504","DOIUrl":null,"url":null,"abstract":"Background Urinary cytology, a non-invasive screening tool, is essential for detecting high-grade urothelial neoplasms. The Paris System (TPS) standardizes reporting practices to improve diagnostic accuracy. TPS 2.0, introduced in 2022, categorizes samples into six diagnostic groups, emphasizing high-grade urothelial carcinoma (HGUC). Materials and Methods This retrospective study analyzed urine cytology samples from June 2023 to May 2024, correlating with histopathology when available. Samples were classified under TPS 2.0 categories, and statistical metrics including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for three groups based on malignancy criteria. Results Out of 180 samples, the distribution was: ND (3.9%), NHGUC (65.6%), AUC (10%), SHGUC (11.7%), and HGUC (8.9%). Histopathological correlation was available for 30.6% of cases. ROM values were: ND (33.3%), NHGUC (29.4%), AUC (66.7%), SHGUC (94.1%), and HGUC (100%). Group A showed the highest sensitivity (86.49%) and diagnostic accuracy (84.62%), while Group C had 100% specificity and PPV. Conclusion The study confirms TPS 2.0's efficacy in improving diagnostic accuracy for HGUC, with high specificity and sensitivity. Compared to TPS 1.0, TPS 2.0 offers clearer diagnostic criteria, enhancing clinical decision-making and patient outcomes. The findings support the continued use of TPS 2.0 in clinical practice, ensuring reliable identification of high-grade urothelial carcinomas.","PeriodicalId":6959,"journal":{"name":"Acta Cytologica","volume":"3 1","pages":"1-13"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cytologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541504","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background Urinary cytology, a non-invasive screening tool, is essential for detecting high-grade urothelial neoplasms. The Paris System (TPS) standardizes reporting practices to improve diagnostic accuracy. TPS 2.0, introduced in 2022, categorizes samples into six diagnostic groups, emphasizing high-grade urothelial carcinoma (HGUC). Materials and Methods This retrospective study analyzed urine cytology samples from June 2023 to May 2024, correlating with histopathology when available. Samples were classified under TPS 2.0 categories, and statistical metrics including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for three groups based on malignancy criteria. Results Out of 180 samples, the distribution was: ND (3.9%), NHGUC (65.6%), AUC (10%), SHGUC (11.7%), and HGUC (8.9%). Histopathological correlation was available for 30.6% of cases. ROM values were: ND (33.3%), NHGUC (29.4%), AUC (66.7%), SHGUC (94.1%), and HGUC (100%). Group A showed the highest sensitivity (86.49%) and diagnostic accuracy (84.62%), while Group C had 100% specificity and PPV. Conclusion The study confirms TPS 2.0's efficacy in improving diagnostic accuracy for HGUC, with high specificity and sensitivity. Compared to TPS 1.0, TPS 2.0 offers clearer diagnostic criteria, enhancing clinical decision-making and patient outcomes. The findings support the continued use of TPS 2.0 in clinical practice, ensuring reliable identification of high-grade urothelial carcinomas.

查看原文本刊更多论文

用于报告尿液细胞学高级别尿路上皮癌的巴黎系统第二版的诊断准确性。

背景尿液细胞学是一种无创筛查工具，对检测高级别尿路肿瘤至关重要。巴黎系统（TPS）对报告方法进行了标准化，以提高诊断的准确性。2022 年推出的 TPS 2.0 将样本分为六个诊断组，并强调高级别尿路上皮癌（HGUC）。材料与方法本回顾性研究分析了 2023 年 6 月至 2024 年 5 月的尿液细胞学样本，并与组织病理学样本进行了关联。样本按 TPS 2.0 分类，并根据恶性程度标准计算了三组样本的敏感性、特异性、阳性预测值 (PPV) 和阴性预测值 (NPV) 等统计指标。结果在 180 个样本中，分布情况如下ND（3.9%）、NHGUC（65.6%）、AUC（10%）、SHGUC（11.7%）和HGUC（8.9%）。30.6%的病例具有组织病理学相关性。ROM 值为ND（33.3%）、NHGUC（29.4%）、AUC（66.7%）、SHGUC（94.1%）和 HGUC（100%）。A 组的灵敏度（86.49%）和诊断准确性（84.62%）最高，而 C 组的特异性和 PPV 均为 100%。结论该研究证实了 TPS 2.0 在提高 HGUC 诊断准确性方面的功效，其特异性和灵敏度都很高。与 TPS 1.0 相比，TPS 2.0 提供了更明确的诊断标准，提高了临床决策和患者预后。研究结果支持在临床实践中继续使用 TPS 2.0，确保可靠地识别高级别尿路上皮癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Cytologica 生物-病理学

CiteScore

3.70

自引率

11.10%

发文量

审稿时长

4-8 weeks

期刊介绍： With articles offering an excellent balance between clinical cytology and cytopathology, ''Acta Cytologica'' fosters the understanding of the pathogenetic mechanisms behind cytomorphology and thus facilitates the translation of frontline research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 national cytology societies around the world, ''Acta Cytologica'' evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlations. Original papers, review articles, meta-analyses, novel insights from clinical practice, and letters to the editor cover topics from diagnostic cytopathology, gynecologic and non-gynecologic cytopathology to fine needle aspiration, molecular techniques and their diagnostic applications. As the perfect reference for practical use, ''Acta Cytologica'' addresses a multidisciplinary audience practicing clinical cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.